DET Stats & Data

DET was first synthesized in 1956 by Hungarian chemist Stephen Szára, with his findings published the following year. More systematic studies were subsequently conducted by Szára and colleagues, as well as independently by Böszörményi and colleagues. Despite being a close structural analog of DMT, DET has remained extremely uncommon with little history of human use outside of clinical research settings. The substance emerged during a period when researchers were investigating the transmethylation hypothesis—the theory that endogenous production of psychoactive agents might explain hallucinatory symptoms in certain psychiatric conditions. This was the era of "psychotomimesis," when scientists sought drugs that could reliably produce states resembling psychosis, hoping such models might inform treatment approaches for mental illness. It was during this period, in 1956, that Humphry Osmond proposed at a New York Academy of Sciences meeting the term "psychedelic" as a less pejorative alternative to existing terminology such as "psychotomimetic." Clinical studies with DET were conducted in the late 1950s and early 1960s under research conditions now recognized as ethically problematic. One study involved unemployed men from a depressed mining area who received intramuscular injections in a partially soundproofed clinic equipped with one-way mirrors and microphones for observation. Other early research was conducted at the Lexington, Kentucky Public Health Service Hospital—a facility that functioned primarily as a federal prison for drug offenders—using hospitalized patients, individuals with schizophrenia, people with alcohol dependence, and prisoners as research subjects.

Effects aggregated from 13 experience reports (13 Erowid)

From 20 individual dose entries

Most common forms and preparations reported

Redosing behavior across 13 reports